This study addresses the intractable“infectioninflammation-injury”vicious cycle in MRSA pneumonia therapy.We have designed a glycosylated mesoporous polydopamine nanoaerosols(MPDA/B@M),which achieves effective treat...This study addresses the intractable“infectioninflammation-injury”vicious cycle in MRSA pneumonia therapy.We have designed a glycosylated mesoporous polydopamine nanoaerosols(MPDA/B@M),which achieves effective treatment of MRSA infected pneumonia through multi mechanism synergistic effects.The aerosol encapsulates bufalin,an active component of traditional Chinese medicine,within MPDA carriers.Surface modification with mannose enables macrophage-targeted delivery.Upon inhalation,the aerosol accumulates efficiently in pulmonary lesions,directly killing pathogens via photothermal effects while releasing bufalin to suppress inflammation.Furthermore,MPDA/B@M scavenges excess reactive oxygen species(ROS)and upregulates heat shock protein 70(HSP70)expression,providing dual cell-protective and antiinflammatory effects.In vitro and in vivo studies demonstrate that MPDA/B@M nanoaerosols achieves 98.2%antibacterial efficacy against MRSA.In MRSA-infected murine pneumonia models,it significantly reduces pulmonary bacterial loads and reprograms macrophage phenotypes to modulate inflammatory responses.This integrated strategy synergizes targeted delivery,antibacterial action,oxidative stress modulation,and anti-inflammatory effects,offering an innovative solution for drug-resistant bacterial pneumonia.展开更多
基金supported by the National Natural Science Foundation of China(No.22173029)the Natural Science Foundation of Nantong Municipal Science and Technology Bureau(No.JC2024011)+2 种基金Excellent Young and Middle-aged Science and Technology Innovation Team Program of Universities in Hubei Province(No.T2024014)the Talent Introduction Project of Hubei Normal University(No.HS2023RC078)the Open Research Fund of Hubei Key Laboratory of Pollutant Analysis&Reuse Technology(No.PA230213).
文摘This study addresses the intractable“infectioninflammation-injury”vicious cycle in MRSA pneumonia therapy.We have designed a glycosylated mesoporous polydopamine nanoaerosols(MPDA/B@M),which achieves effective treatment of MRSA infected pneumonia through multi mechanism synergistic effects.The aerosol encapsulates bufalin,an active component of traditional Chinese medicine,within MPDA carriers.Surface modification with mannose enables macrophage-targeted delivery.Upon inhalation,the aerosol accumulates efficiently in pulmonary lesions,directly killing pathogens via photothermal effects while releasing bufalin to suppress inflammation.Furthermore,MPDA/B@M scavenges excess reactive oxygen species(ROS)and upregulates heat shock protein 70(HSP70)expression,providing dual cell-protective and antiinflammatory effects.In vitro and in vivo studies demonstrate that MPDA/B@M nanoaerosols achieves 98.2%antibacterial efficacy against MRSA.In MRSA-infected murine pneumonia models,it significantly reduces pulmonary bacterial loads and reprograms macrophage phenotypes to modulate inflammatory responses.This integrated strategy synergizes targeted delivery,antibacterial action,oxidative stress modulation,and anti-inflammatory effects,offering an innovative solution for drug-resistant bacterial pneumonia.
